Physician profile
Arjun Trivedi
NPI 1073169132
$1,089.30
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $234 · 2023: $569 · 2024: $286.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $855.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $854.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $248.23 | 2022-2024 | Tepezza |
| Ascendis Pharma Endocrinology INC | $227.67 | 2023 | |
| Medtronic, INC. | $180.34 | 2023-2024 | Minimed 780g, Minimed 770g |
| Lantheus Medical Imaging, INC. | $124.74 | 2023 | Definity |
| E.R. Squibb & Sons, L.L.C. | $92.14 | 2022 | |
| Novo Nordisk INC | $47.77 | 2023-2024 | Ozempic |
| Alnylam Pharmaceuticals INC. | $35.83 | 2023 | Givlaari |
| Abbvie INC. | $28.55 | 2024 | |
| Abbott Laboratories | $23.88 | 2024 | Freestyle Libre 3 |
| Edwards Lifesciences Corporation | $19.94 | 2022 | |
| Dexcom, INC. | $16.14 | 2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.11 | 2023 | Jardiance |
| Averitas Pharma INC. | $14.40 | 2023 | Qutenza |
| Astrazeneca Pharmaceuticals LP | $13.56 | 2023 | Lokelma |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arjun Trivedi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.